Zonisamide for the treatment of Parkinson’s disease

References

• Leppik Ilo E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure13(Suppl. 1), S5–S10 (2004).
   Google Scholar
• Arzimanoglou A, Rahbani A. Zonisamide for the treatment of epilepsy. Expert Rev. Neurother.6, 1283–1292 (2006).
   PubMed Web of Science ®Google Scholar
• Fukushima K, Seino M. A long-term follow-up of zonisamide monotherapy. Epilepsia47, 1860–1864 (2006).
   PubMedGoogle Scholar
• Ohtahara S. Zonisamide in the management of epilepsy – Japanese experience. Epilepsy Res.68(Suppl. 2), S25–S33 (2006).
   PubMed Web of Science ®Google Scholar
• Drake ME Jr, Greathouse NI, Renner JB, Armentbright AD. Open-label zonisamide for refractory migraine. Clin. Neuropharmacol.27, 278–280 (2004).
   PubMed Web of Science ®Google Scholar
• Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA289, 1820–1825 (2003).
   PubMed Web of Science ®Google Scholar
• Wilson MS, Findling RL. Zonisamide for bipolar depression. Expert Opin. Pharmacother.8, 111–113 (2007).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Kotwal R, Guerdjikova AI. et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J. Clin. Psychiatry67, 1897–1906 (2006).
   PubMed Web of Science ®Google Scholar
• Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med.6(3), 225–234 (2005).
   PubMed Web of Science ®Google Scholar
• Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson’s disease patients. Neurosci. Res.41, 397–399 (2001).
   PubMed Web of Science ®Google Scholar
• Murata M, Hasegawa K, Kanazawa I. The Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology68, 45–50 (2007).
   PubMed Web of Science ®Google Scholar
• Bonuccelli U, Del Dotto P. New pharmacologic horizons in the treatment of Parkinson disease. Neurology67(7 Suppl. 2), S30–S38 (2006).
   Web of Science ®Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientificrationale and clinical implications. Lancet Neurol.5, 677–687 (2006).
   PubMed Web of Science ®Google Scholar
• Stocchi F. Optimising levodopa therapy for the management of Parkinson’s disease. J. Neurol.252(Suppl. 4), IV43–IV48 (2005).
   PubMedGoogle Scholar
• Uno H, Kurokawa M, Masuda Y, Nishimura H. Studies on 3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. J. Med. Chem.22, 180–183 (1979).
   PubMed Web of Science ®Google Scholar
• Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure5, 115–119 (1996).
   PubMed Web of Science ®Google Scholar
• Okada M, Kaneko S, Hirano T et al. Effects of zonisamide on dopaminergic system. Epilepsy Res.22, 193–205 (1995).
   PubMed Web of Science ®Google Scholar
• Okada M, Hirano T, Kawata Y et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res.34, 187–197 (1999).
   PubMed Web of Science ®Google Scholar
• Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res.3, 138–143 (1989).
   PubMed Web of Science ®Google Scholar
• Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H. Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med. J. Osaka Univ.39, 13–17 (1990).
   PubMedGoogle Scholar
• Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Mol. Brain Res.116, 1–6 (2003).
   PubMedGoogle Scholar
• Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson’s disease. Curr. Pharm. Des.10, 687–693 (2004).
   PubMed Web of Science ®Google Scholar
• Gluck MR, Santana LA, Granson H, Yahr MD. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson’s activity. J. Neural Transm.111, 713–724 (2004).
   PubMed Web of Science ®Google Scholar
• Wichmann T, DeLong MR. Basal ganglia discharge abnormalities in Parkinson’s disease. J. Neural Transm.70, 21–25 (2006).
   Google Scholar
• Wang L, Kitai ST, Xiang Z. Activity-dependent bidirectional modification of inhibitory synaptic transmission in rat subthalamic neurons. J. Neurosci.26, 7321–7327 (2006).
   PubMedGoogle Scholar
• Wolfart J, Roeper J. Selective coupling of T-type calcium channels to SK potassium channels prevents intrinsic bursting in dopaminergic midbrain neurons. J. Neurosci.22, 3404–3413 (2002).
   PubMed Web of Science ®Google Scholar
• Gomez-Mancilla B, Latulippe JF, Boucher R, Bedard PJ. Effect of ethosuximide on rest tremor in the MPTP monkey model. Mov. Disord.7, 137–141 (1992).
   PubMed Web of Science ®Google Scholar
• Pourcher E, Gomez-Mancilla B, Bedard PJ. Ethosuximide and tremor in Parkinson’s disease: a pilot study. Mov. Disord.7, 132–136 (1992).
   PubMedGoogle Scholar
• Minato H, Kikuta C, Fujitani B, Masuda Y. Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats. Epilepsia38, 975–980 (1997).
   PubMed Web of Science ®Google Scholar
• Owen AJ, Ijaz S, Miyashita H, Wishart T, Howlett W, Shuaib A. Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioral study. Brain Res.770, 115–122 (1997).
   PubMed Web of Science ®Google Scholar
• Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res.30, 153–158 (1998).
   PubMed Web of Science ®Google Scholar
• Noda Y, Mori A, Packer L. Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus. Res. Commun. Mol. Pathol. Pharmacol.105, 23–33 (1999).
   PubMed Web of Science ®Google Scholar
• Komatsu M, Hiramatsu M, Willmore LJ. Zonisamide reduces the increase in 8-hydroxy-2´-deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats. Epilepsia41, 1091–1094 (2000).
   PubMed Web of Science ®Google Scholar
• Nakasa H, Nakamura H, Ono S et al. Prediction of drug–drug interactions of zonisamide metabolism in humans from in vitro data. Eur. J. Clin. Pharmacol.54, 177–83 (1998).
   PubMed Web of Science ®Google Scholar
• Ohmori S, Nakasa H, Asanome K et al. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim. Biophys. Acta1380, 297–304 (1998).
   PubMed Web of Science ®Google Scholar
• Stiff DD, Robicheau JT, Zemaitis MA. Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative. Xenobiotica22, 1–11 (1992).
   PubMed Web of Science ®Google Scholar
• Murata M, Hasegawa K, Kanazawa I. Randomized, double-blind study of zonisamide with placebo in advanced Parkinson’s disease. Move. Disord.19(Suppl. 9), S198 (2004).
   Google Scholar
• Nakanishi I, Kohmoto J, Miwa H, Kondo T. Effect of zonisamide on resting tremor resistant to antiparkinsonian medication. No To Shinkei55, 685–689 (2003) (In Japanese).
   PubMedGoogle Scholar
• Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat. Disord.11, 101–103 (2005).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Khan F. Zonisamide for essential tremor. Move. Disord.21(Suppl. 15), S705 (2006).
   Google Scholar
• Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Move. Disord.22, 279–282 (2007).
   PubMed Web of Science ®Google Scholar
• Miwa H, Hama K, Kajimoto Y, Kondo T. Effects of zonisamide on experimental tremors in rats. Parkinsonism Relat. Disord. (2007) (In Press).
   PubMedGoogle Scholar
• Ondo WG. Essential tremor: treatment options. Curr. Treat. Options Neurol.8, 256–267 (2006).
   PubMedGoogle Scholar